Evidence map›Paper›PMID 40654351›Full record

ArticleActa pharmaceutica Sinica. B2025

Tranexamic acid-fatty alcohol polyoxyethylene ether conjugation/PVA foam for venous sclerotherapy

Jizhuang Ma, Keda Zhang, Wenhan Li, Yu Ding, Yongfeng Chen, Xiaoyu Huang, Tong Yu, Di Song, Haoran Niu, Huichao Xie and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jizhuang MaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Keda ZhangCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Wenhan LiUltrasound Department, Shengjing Hospital, China Medical University, Shenyang 110016, China.
Yu DingSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yongfeng ChenSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Xiaoyu HuangSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Tong YuSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Di SongSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Haoran NiuSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Huichao XieCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Tianzhi YangDepartment of Basic Pharmaceutical Sciences, School of Pharmacy, Husson University, Bangor, ME 04401, USA.
Xiaoyun ZhaoSchool of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
Xinggang YangSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
Pingtian DingCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venous system diseases mainly include varicose veins and venous malformations of lower limbs and the genital system. Most of them are chronic diseases that cause serious clinical symptoms to patients and affect their health and quality of life. Sclerotherapy has become the first-line therapy for venous system diseases. However, there are problems such as incomplete fibrosis and vascular recanalization after sclerotherapy, and improper operation will cause serious adverse consequences. Therefore, exploring a safe and effective sclerotherapy strategy is essential for developing clinically successful sclerotherapy. To solve the above problems, we proposed a new sclerotherapy strategy with a dual mechanism of "vascular damage and plasmin (PLA) system inhibition." We intended to construct a novel cationic surfactant (AEO

Indexed as

Fatty alcohol polyoxyethylene etherFibrosisFoam preparationMatrix metalloproteinasesPlasmin systemSclerotherapyTranexamic acidVenous malformations

Identifiers

PMID40654351
PMCPMC12254752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.